Experimental Models for Renal Diseases

Pathogenesis and Diagnosis

Editor(s): Herrera G.A. (Tempe, Ariz.) 
Table of Contents
Vol. 169, 2011
Section title: Paper

Kidney Microvasculature in Health and Disease

Jen K.-Y. · Haragsim L. · Laszik Z.G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The renal microvasculature is composed of the glomerular and peritubular capillary beds which supply the cellular constituents of the kidney with oxygen and nutrients as well as maintain renal function by providing an adequate glomerular filtration rate. As a result, endothelial dysfunction within the kidney can lead to devastating consequences. Recently, a plethora of information regarding the molecular players involved in kidney microvasculature development and disease has emerged. Many of these studies focus on intricate signaling pathways within the local microenvironment of endothelial cells. Here, we highlight some of these studies and relate them to the molecular pathogenesis of glomerular and peritubular endothelialcells in both native and transplant renal diseases.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bernstein J Cheng F Roszka J: Glomerular differentiation in metanephric culture. Lab Invest 1981; 45: 183-190
  2. Ekblom P: The origin of the glomerular endothelium. Cell Differ 1982; 11: 35-39
  3. Sariola H: Differentiation and vascularization of the metanephric kidney grafted on the chorioallantoic membrane. Dev Biol 1983; 96: 427-435
  4. Sariola H: Dual origin of glomerular basement membrane. Dev Biol 1984; 101: 86-96
  5. Rogers SA Hammerman MR: Transplantation of rat metanephroi into mice. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1865-R1869
  6. Takeda S Rogers SA Hammerman MR: Differential origin for endothelial and mesangial cells after transplantation of pig fetal renal primordia into rats. Transpl Immunol 2006; 15: 211-215
  7. Hyink DP: Endogenous origin of glomerular endothelial and mesangial cells in grafts of embryonic kidneys. Am J Physiol 1996; 270: F886-F899
  8. Robert B: Evidence that embryonic kidney cells expressing flk-1 are intrinsic, vasculogenic angioblasts. Am J Physiol 1996; 271: F744-F753
  9. Abrahamson DR Robert B: Derivation and differentiation of glomerular endothelial cells. Nephrol Dial Transplant 2003; 18: ((Suppl 6)) vi2-vi7
  10. Vaughan MR Quaggin SE: How do mesangial and endothelial cells form the glomerular tuft?. J Am Soc Nephrol 2008; 19: 24-33
  11. Quaggin SE Kreidberg JA: Development of the renal glomerulus: good neighbors and good fences. Development 2008; 135: 609-620
  12. Dressler GR: The cellular basis of kidney development. Annu Rev Cell Dev Biol 2006; 22: 509-529
  13. Ballermann BJ: Glomerular endothelial cell differentiation. Kidney Int 2005; 67: 1668-1671
  14. Fierlbeck W: Endothelial cell apoptosis during glomerular capillary lumen formation in vivo. J Am Soc Nephrol 2003; 14: 1349-1354
  15. Lindahl P: Paracrine PDGF-B/PDGF-Rbeta signaling controls mesangial cell development in kidney glomeruli. Development 1998; 125: 3313-3322
  16. Leveen P: Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994; 8: 1875-1887
  17. Soriano P: Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994; 8: 1888-1896
  18. Kikkawa Y Virtanen I Miner JH: Mesangial cells organize the glomerular capillaries by adhering to the G domain of laminin alpha5 in the glomerular basement membrane. J Cell Biol 2003; 161: 187-196
  19. Sariola H: Incomplete fusion of the epithelial and endothelial basement membranes in interspecies hybrid glomeruli. Cell Differ 1984; 14: 189-195
  20. St John PL Abrahamson DR: Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and -11 chains. Kidney Int 2001; 60: 1037-1046
  21. Ballermann BJ: Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 2007; 106: 19-25
  22. Satchell SC Braet F: Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 2009; 296: F947-F956
  23. Ballermann BJ Stan RV: Resolved: capillary endothelium is a major contributor to the glomerular filtration barrier. J Am Soc Nephrol 2007; 18: 2432-2438
  24. Avasthi PS: Effect of gentamicin on glomerular ultrastructure. J Lab Clin Med 1981; 98: 444-454
  25. Deen WM Lazzara MJ Myers BD: Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 2001; 281: F579-F596
  26. Lafayette RA: Nature of glomerular dysfunction in pre-eclampsia. Kidney Int 1998; 54: 1240-1249
  27. Farquhar MG Wissig SL Palade GE: Glomerular permeability. I. Ferritin transfer across the normal glomerular capillary wall. J Exp Med 1961; 113: 47-66
  28. Stan RV Kubitza M Palade GE: PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc Natl Acad Sci USA 1999; 96: 13203-13207
  29. Ryan GB Hein SJ Karnovsky MJ: Glomerular permeability to proteins. Effects of hemodynamic factors on the distribution of endogenous immunoglobulin G and exogenous catalase in the rat glomerulus. Lab Invest 1976; 34: 415-427
  30. Ryan GB Karnovsky MJ: Distribution of endogenous albumin in the rat glomerulus: role of hemodynamic factors in glomerular barrier function. Kidney Int 1976; 9: 36-45
  31. Rostgaard J Qvortrup K: Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res 1997; 53: 1-13
  32. Rostgaard J Qvortrup K: Sieve plugs in fenestrae of glomerular capillaries-site of the filtration barrier. Cells Tissues Organs 2002; 170: 132-138
  33. Hjalmarsson C Johansson BR Haraldsson B: Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res 2004; 67: 9-17
  34. Jeansson M Haraldsson B: Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 2006; 290: F111-F116
  35. Henao DE: Preeclamptic sera directly induce slit-diaphragm protein redistribution and alter podocyte barrier-forming capacity. Nephron Exp Nephrol 2008; 110: e73-e81
  36. Collino F: Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008; 294: F1185-F1194
  37. Ferrara N: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442
  38. Carmeliet P: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439
  39. Shalaby F: Failure of bloodisland formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66
  40. Fong GH: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70
  41. Fong GH: Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999; 126: 3015-3025
  42. Waltenberger J: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26995
  43. Gille H: Analysis of biological effects and signaling properties of Flt1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001; 276: 3222-3230
  44. Gille H: A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3’ -kinase activation and endothelial cell migration. EMBO J 2000; 19: 4064-4073
  45. Hiratsuka S: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-9354
  46. Brown LF: Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 1457-1461
  47. Simon M: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995; 268: F240-F250
  48. Kitamoto Y Tokunaga H Tomita K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: glome rulogenesis and nephrogenesis. J Clin Invest 1997; 99: 2351-2357
  49. Sugimoto H: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608
  50. Eremina V: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716
  51. Eremina V: Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735
  52. Korgaonkar SN: HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008; 19: 877-883
  53. Tufro A: VEGF spatially directs angiogenesis during metanephric development in vitro. Dev Biol 2000; 227: 558-566
  54. Eremina V Baelde HJ Quaggin SE: Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106: p32-p37
  55. Bates DO: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62: 4123-4131
  56. Woolard J: VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-7835
  57. Bevan HS: The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol 2008; 110: p57-p67
  58. Mattot V: Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002; 13: 1548-1560
  59. Stalmans I: Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002; 109: 327-336
  60. Soker S: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745
  61. Whitaker GB Limberg BJ Rosenbaum JS: Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem 2001; 276: 25520-25531
  62. Robert B Zhao X: Abrahamson DR: Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli. Am J Physiol Renal Physiol 2000; 279: F275-F282
  63. Robinson CJ: VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 2006; 281: 1731-1740
  64. Reidy KJ: Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. Development 2009; 136: 3979-3989
  65. Tapia R: Semaphorin3a disrupts podocyte foot processes causing acute proteinuria. Kidney Int 2008; 73: 733-740
  66. Wilkinson L: CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 2003; 278: 34181-34188
  67. Pennisi DJ: Crim1 KST264/KST264 mice display a disruption of the Crim1 gene resulting in perinatal lethality with defects in multiple organ systems. Dev Dyn 2007; 236: 502-511
  68. Wilkinson L: Crim1KST264/KST264 mice implicate Crim1 in the regulation of vascular endothelial growth factor-A activity during glomerular vascular development. J Am Soc Nephrol 2007; 18: 1697-1708
  69. Liu A Dardik A Ballermann BJ: Neutralizing TGF-beta1 antibody infusion in neonatal rat delays in vivo glomerular capillary formation 1. Kidney Int 1999; 56: 1334-1348
  70. Choi ME Ballermann BJ: Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J Biol Chem 1995; 270: 21144-21150
  71. Ferrari G: Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 2009; 219: 449-458
  72. Ferrari G: VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci USA 2006; 103: 17260-17265
  73. Woolf AS Gnudi L Long DA: Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 2009; 20: 239-244
  74. Yuan HT: Expression of angiopoietin-1, angiopoietin-2, and the Tie-2 receptor tyrosine kinase during mouse kidney maturation. J Am Soc Nephrol 1999; 10: 1722-1736
  75. Kolatsi-Joannou M: Expression and potential role of angiopoietins and Tie-2 in early development of the mouse metanephros. Dev Dyn 2001; 222: 120-126
  76. Satchell SC: Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002; 13: 544-550
  77. Suri C: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180
  78. Davis B: Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 2007; 18: 2320-2329
  79. Partanen J: Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 1996; 122: 3013-3021
  80. McCright B: Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development 2001; 128: 491-502
  81. Cheng HT Kopan R: The role of Notch signaling in specification of podocyte and proximal tubules within the developing mouse kidney. Kidney Int 2005; 68: 1951-1952
  82. Niranjan T: The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14: 290-298
  83. Waters AM: Ectopic notch activation in developing podocytes causes glomerulosclerosis. J Am Soc Nephrol 2008; 19: 1139-1157
  84. Miner JH Building the glomerulus: a matricentric view. J Am Soc Nephrol 2005; 16: 857-861
  85. Miner JH Li C: Defective glomerulogenesis in the absence of laminin alpha5 demonstrates a developmental role for the kidney glomerular basement membrane. Dev Biol 2000; 217: 278-289
  86. Abrass CK: Abnormal development of glomerular endothelial and mesangial cells in mice with targeted disruption of the lama3 gene. Kidney Int 2006; 70: 1062-1071
  87. Takabatake Y: The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol 2009; 20: 1714-1723
  88. Ueda H: Bmp in podocytes is essential for normal glomerular capillary formation. J Am Soc Nephrol 2008; 19: 685-694
  89. Zoccali C: The endothelium as a target in renal diseases. J Nephrol 2007; 20: ((Suppl 12)) S39-S44
  90. Stillman IE Karumanchi SA: The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18: 2281-2284
  91. Levine RJ: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
  92. Maynard SE: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
  93. Li Z: Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-692
  94. Bergmann A: Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2009; E-pub ahead of print
  95. Izzedine H: Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007; 50: 203-218
  96. Gurevich F Perazella MA: Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122: 322-328
  97. Wallukat G: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945-952
  98. Grill S: Potential markers of preeclampsia - a review. Reprod Biol Endocrinol 2009; 7: 70
  99. Zhou CC: Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14: 855-862
  100. Zhou CC: Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51: 1010-1019
  101. Venkatesha S: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649
  102. Yinon Y: Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008; 172: 77-85
  103. Levine RJ: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005
  104. Fine LG Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872
  105. Fine LG Orphanides C Norman JT: Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl 1998; 65: S74-S78
  106. Bohle A Mackensen-Haen S Wehrmann M: Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996; 19: 191-195
  107. Kang DH: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1 J Am Soc Nephrol 2001; 12: 1434-1447
  108. Ohashi R Kitamura H Yamanaka N: Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000; 11: 47-56
  109. Ohashi R: Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 2002; 13: 1795-1805
  110. Shimizu A: Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 1997; 151: 1231-1239
  111. Kitamura H: Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model. Exp Nephrol 1998; 6: 328-336
  112. Rizkalla B: Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the reninangiotensin system. J Hypertens 2005; 23: 153-164
  113. Yuan HT: Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int 2002; 61: 2078-2089
  114. Lu YH: Changes in angiopoietin expression in glomeruli involved in glomerulosclerosis in rats with daunorubicin-induced nephrosis. Acta Pharmacol Sin 2006; 27: 579-587
  115. Kang DH: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function J Am Soc Nephrol 2001; 12: 1448-1457
  116. Futrakul N Butthep P Futrakul P: Altered vascular homeostasis in chronic kidney disease. Clin Hemorheol Microcirc 2008; 38: 201-207
  117. Futrakul N: A defective angiogenesis in chronic kidney disease. Ren Fail 2008; 30: 215-217
  118. Choi YJ: Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 2000; 31: 1491-1497
  119. Di Marco GS: The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20: 2235-2245
  120. Baylis C: Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008; 294: F1-F9
  121. Mattson DL: Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol 1994; 266: H1918-H1926
  122. Gardiner SM: Nitric oxide synthase inhibitors cause sustained, but reversible, hypertension and hindquarters vasoconstriction in Brattleboro rats. Eur J Pharmacol 1992; 213: 449-451
  123. Shesely EG: Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93: 13176-13181
  124. Huang PL: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242
  125. Herrera M Garvin JL: Recent advances in the regulation of nitric oxide in the kidney. Hypertension 2005; 45: 1062-1067
  126. Passauer J: Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 2005; 16: 959-965
  127. Zoccali C: Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24: 611-619
  128. Kielstein JT: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177
  129. Xiao S: Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 2001; 59: 1466-1472
  130. Fliser D: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461
  131. Ravani P: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455
  132. Matsuguma K: Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176-2183
  133. O’Riordan E: Chronic NOS inhibition actuates endothelialmesenchymal transformation. Am J Physiol Heart Circ Physiol 2007; 292: H285-H294
  134. Singh P: The balance of angiotensin II and nitric oxide in kidney diseases. Curr Opin Nephrol Hypertens 2008; 17: 51-56
  135. Joles JA Willekes-Koolschijn N Koomans HA: Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int 1997; 52: 761-770
  136. Kang DH: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-816
  137. Norman JT: Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action. Nephron Physiol 2003; 94: p39-p46
  138. Kang DH: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161: 239-248
  139. Zhou X Frohlich ED: Ageing, hypertension and the kidney: new data on an old problem. Nephrol Dial Transplant 2003; 18: 1442-1445
  140. Glassock RJ Winearls C: Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 2009; 120: 419-428
  141. Futrakul N Futrakul P: Renal microvascular disease in an aging population: a reversible process?. Ren Fail 2008; 30: 353-356
  142. Baylis C: Changes in renal hemodynamics and structure in the aging kidney; sexual dimorphism and the nitric oxide system. Exp Gerontol 2005; 40: 271-278
  143. Thomas SE: Tubulointerstitial disease in aging: evidence for underlying peritubular capillary damage, a potential role for renal ischemia. J Am Soc Nephrol 1998; 9: 231-242
  144. McLachlan MS: The ageing kidney. Lancet 1978; 2: 143-145
  145. Kang DH: Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001; 37: 601-611
  146. Shimada T: Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004; 110: 1148-1155
  147. Xiong Y: Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. Clin Exp Pharmacol Physiol 2001; 28: 842-847
  148. Lu R: Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats. Comp Med 2002; 52: 224-228
  149. Kielstein JT: Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895
  150. Forte P: Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 1998; 32: 730-734
  151. Baylis C: Sexual dimorphism in the aging kidney: differences in the nitric oxide system. Nat Rev Nephrol 2009; 5: 384-396
  152. Reckelhoff JF: Gender differences in the renal nitric oxide (NO) system: dissociation between expression of endothelial NO synthase and renal hemodynamic response to NO synthase inhibition. Am J Hypertens 1998; 11: 97-104
  153. Racusen LC: Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714
  154. Colvin RB Smith RN: Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817
  155. Truong LD: Acute antibody-mediated rejection of renal transplant: pathogenetic and diagnostic considerations. Arch Pathol Lab Med 2007; 131: 1200-1208
  156. Sis B Halloran PF: Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15: 42-48
  157. Sis B: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323
  158. Solez K: Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760
  159. Gloor JM: Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132
  160. Nankivell BJ: Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 461-468
  161. Fotheringham J Angel CA McKane W: Transplant glomerulopathy: morphology, associations and mechanism. Nephron Clin Pract 2009; 113: c1-c7 discussion c7

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50